A Phase 2 interventional study of Blinatumomab and TKI in Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia and Minimal Residual Disease, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing blinatumomab in Burkitt Lymphoma — 16 open to participants now, 23 under way, 8 of them phase 3. blinatumomab · Burkitt Lymphoma.
Among the 35 studies testing blinatumomab in Burkitt Lymphoma, this one is the 20th largest by enrollment, is the only one that started in 2015, is one of 17 in phase 2, and was the 5th registered.
978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.
Browse Burkitt Lymphoma studies →16 of the 35 studies testing blinatumomab in Burkitt Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Austria, Belgium, Czechia and 18 more countries
Ages 1+
City of Hope Medical Center · Sites in United States
Ages 12–55
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages up to 365 days
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1–18
By country, each count listing its studies:
blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 25 · Phase 3 8
First in 2010; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 36 across 767 interventional studies indexed under Burkitt Lymphoma.
Median enrollment 52 across the 35 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 35 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
34 studies in Burkitt Lymphoma by M.D. Anderson Cancer Center: 5 open now, 7 under way, none of them phase 3. Of 20 finished, 14 (70%) have results posted.
Among the 34 studies in Burkitt Lymphoma by M.D. Anderson Cancer Center, this one is the 13th largest by enrollment, is one of 4 that started in 2015, is one of 17 in phase 2, and was the 17th registered.
M.D. Anderson Cancer Center’s Burkitt Lymphoma studies by the year they started, since 1998.
2 of the studies testing blinatumomab in Burkitt Lymphoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03914625Phase 3National Cancer Institute (NCI)A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | 2027-09-30 |
| NCT03739814National Cancer Institute (NCI)Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies testing blinatumomab in Burkitt Lymphoma, from their registry updates:
Among M.D. Anderson Cancer Center’s 34 in Burkitt Lymphoma:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in the body (minimal residual disease). Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
PRIMARY OBJECTIVES:
I. To evaluate the clinical efficacy of blinatumomab in patients B-cell acute lymphoblastic leukemia in complete morphologic remission with positive minimal residual disease (MRD) in terms of relapse-free survival (RFS).
SECONDARY OBJECTIVES:
I. To evaluate other efficacy endpoints such as overall survival and MRD negativity rate by flow cytometry and/or polymerase chain reaction (PCR) overall and after the first cycle, as well as safety of blinatumomab in this setting.
OUTLINE:
Patients receive blinatumomab intravenously (IV) continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.
After completion of study treatment, patients are followed up every 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.
Biological: Blinatumomab
Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received. A TKI will be added at the discretion of the treating physician.
Biological: Blinatumomab · Other: TKI
Given IV
Also known as: Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103
A TKI will be added at the discretion of the treating physician.
Relapse-free Survival (RFS)
RFS is relapse-free survival, which is defined as the time interval from date of treatment start until the date of death or hematologic or extramedullary disease relapse. Patients who are alive and relapsefree at the last follow-up date will be censored at that time. In addition, patients who drop off the study due to receiving allogeneic stem cell transplantation will be censored at the time off study.
Time frame: From the date of treatment start until the date of death, relapse or discontinuation due to receiving allogeneic stem cell transplantation, assessed up to 112 months.
Overall Survival (OS)
Time from date of treatment start until date of death due to any cause.
Time frame: From treatment start to the date of death or last follow-up, whichever occurred first, Up to 10 years, and 1 day
Number of Patients MRD Negative Overall
MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4. For patients with Ph+ ALL, MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4 AND absence of a quantifiable PCR for BCR-ABL1 by PCR with a sensitivity of at least 10\^-4 or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% for patients with non-p210 transcripts
Time frame: Up to 10 years and 1 day
Number of Participants Who Were MRD Negative After Course 1
MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4. For patients with Ph+ ALL, MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4 AND absence of a quantifiable PCR for BCR-ABL1 by PCR with a sensitivity of at least 10\^-4 or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% for patients with non-p210 transcripts
Time frame: Up to 6 weeks
| Milestone | Treatment (Blinatumomab) | Treatment (Blinatumomab + TKI) |
|---|---|---|
| Started | 19 | 18 |
| Completed | 19 | 18 |
| Not completed | 0 | 0 |
RFS is relapse-free survival, which is defined as the time interval from date of treatment start until the date of death or hematologic or extramedullary disease relapse. Patients who are alive and relapsefree at the last follow-up date will be censored at that time. In addition, patients who drop off the study due to receiving allogeneic stem cell transplantation will be censored at the time off study.
| Months | Treatment (Blinatumomab) | Treatment (Blinatumomab + TKI) |
|---|---|---|
| Relapse-free Survival (RFS) | 11.6 (0.9 to 110.4) | 25.0 (1.4 to 81.5) |
Time from date of treatment start until date of death due to any cause.
| Months | Treatment (Blinatumomab) | Treatment (Blinatumomab + TKI) |
|---|---|---|
| Overall Survival (OS) | 60.8 (3.6 to 116.0) | NA (5.1 to 104.5) |
MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4. For patients with Ph+ ALL, MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4 AND absence of a quantifiable PCR for BCR-ABL1 by PCR with a sensitivity of at least 10\^-4 or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% for patients with non-p210 transcripts
| Participants | Treatment (Blinatumomab) | Treatment (Blinatumomab + TKI) |
|---|---|---|
| Number of Patients MRD Negative Overall | 16 | 11 |
MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4. For patients with Ph+ ALL, MRD negativity is defined as undetectable MRD by flow cytometry with a sensitivity of at least 10\^-4 AND absence of a quantifiable PCR for BCR-ABL1 by PCR with a sensitivity of at least 10\^-4 or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% according to the International Scale for patients with p210 transcript or a ratio of BCR-ABL1 to ABL1 by PCR of \< 0.01% for patients with non-p210 transcripts
| Participants | Treatment (Blinatumomab) | Treatment (Blinatumomab + TKI) |
|---|---|---|
| Number of Participants Who Were MRD Negative After Course 1 | 15 | 9 |
Collected over Up to 10 years, and 1 day. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment (Blinatumomab) | 11/19 (57.9%) | 12/19 (63.2%) | 10/19 (52.6%) |
| Treatment (Blinatumomab) + TKI | 6/18 (33.3%) | 11/18 (61.1%) | 12/18 (66.7%) |
| Event | Treatment (Blinatumomab) | Treatment (Blinatumomab) + TKI |
|---|---|---|
| FeverGeneral disorders | 0/19 | 5/18 |
| Lung InfectionInfections and infestations | 1/19 | 3/18 |
| CRS: cytokine release syndromeImmune system disorders | 2/19 | 0/18 |
| PAINGeneral disorders | 2/19 | 0/18 |
| Altered Mental StatusNervous system disorders | 0/19 | 1/18 |
| Catheter related infectionInfections and infestations | 0/19 | 1/18 |
| Chest painCardiac disorders | 0/19 | 1/18 |
| ConfusionPsychiatric disorders | 0/19 | 1/18 |
| ConstipationGastrointestinal disorders | 0/19 | 1/18 |
| Enterocolitis infectiousInfections and infestations | 0/19 | 1/18 |
| Event | Treatment (Blinatumomab) | Treatment (Blinatumomab) + TKI |
|---|---|---|
| FeverGeneral disorders | 0/19 | 7/18 |
| Abdominal painGastrointestinal disorders | 0/19 | 4/18 |
| ALT increasedInvestigations | 0/19 | 4/18 |
| Creatinine increasedInvestigations | 0/19 | 4/18 |
| DiarrheaGastrointestinal disorders | 0/19 | 3/18 |
| FatigueGeneral disorders | 0/19 | 3/18 |
| Lung InfectionInfections and infestations | 1/19 | 3/18 |
| ConfusionPsychiatric disorders | 3/19 | 2/18 |
| Altered Mental StatusNervous system disorders | 0/19 | 2/18 |
| Back painMusculoskeletal and connective tissue disorders | 0/19 | 2/18 |
| Age, Categorical(Participants) | Treatment (Blinatumomab) | Treatment (Blinatumomab) + TKI | Total |
|---|---|---|---|
| <=18 years | 1 | 0 | 1 |
| Between 18 and 65 years | 17 | 16 | 33 |
| >=65 years | 1 | 2 | 3 |
| Age, Continuous(years) | Treatment (Blinatumomab) | Treatment (Blinatumomab) + TKI | Total |
|---|---|---|---|
| Median | 42 (18 to 66) | 43 (21 to 83) | 42 (18 to 83) |
| Sex: Female, Male(Participants) | Treatment (Blinatumomab) | Treatment (Blinatumomab) + TKI | Total |
|---|---|---|---|
| Female | 10 | 6 | 16 |
| Male | 9 | 12 | 21 |
| Race (NIH/OMB)(Participants) | Treatment (Blinatumomab) | Treatment (Blinatumomab) + TKI | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 5 |
| White | 15 | 12 | 27 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(participants) | Treatment (Blinatumomab) | Treatment (Blinatumomab) + TKI | Total |
|---|---|---|---|
| United States | 19 | 18 | 37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Sep 2025, 120 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 84 non-industry phase 2 interventional studies under Burkitt Lymphoma, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's 120 months is above that.
Counting every sponsor, half of 92 studies reached it within 81 months; a quarter within 41 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab